20 hrs ago
Gilead CEO John Martin pockets $19 million in stock sale
Gilead Sciences Inc. Chairman and CEO John Martin made nearly $19 million by selling 282,242 shares Monday at nearly 10 times the price at which he exercised options to buy the shares.
New target identified for preventing bone destruction in diseases such as arthritis and cancer
The skeleton is constantly being remodelled by the breakdown of old bone by cells called osteoclasts and the formation of new bone by cells called osteoblasts.
Mon Dec 02, 2013
Gilead Sciences to Present at the Nasdaq Omx 30th Investor Program on Tuesday, December 3
Gilead Sciences, Inc. today announced that its corporate presentation will be webcast from the NASDAQ OMX 30th Investor Program in London.
Weekly Top Insider Sells: GOOG, FCX, GILD, P, OCN
According to GuruFocus Insider Data , the largest insider sells during the past week were: Google Inc, Freeport-McMoRan Copper & Gold, Gilead Sciences Inc, Pandora Media Inc, and Ocwen Financial Corporation.
Gilead Sciences, Inc. Uses the PHT Corporation LogPad System for 1st...
World's most widely used ePRO System leveraged on 14-country, 104-site, 927-patient trial; primary and secondary endpoints achieved, with 98% patient compliance )--The PHT Corporation LogPadA System was used by Gilead Sciences, Inc. on the Phase 4 TERISA trial which measured the antianginal effect of Ranolazine in T2DM patients in the therapeutic ... (more)
Idenix Pharmaceuticals Files Patent Infringement, Interference Lawsuits Against Gilead Sciences
Idenix Pharmaceuticals today announced that it has filed two lawsuits against Gilead Sciences, Inc. : a patent infringement lawsuit in the United States District Court in Boston, Massachusetts and a separate patent infringement and interference lawsuit in the United States District Court in Wilmington, Delaware.
Thu Nov 28, 2013
Wed Nov 27, 2013
Early Morning Buzz: Groupon, Gilead Sciences, Eltek Ltd, Alcatel...
There are gimmicks and then there are gimmicks. Groupon, Inc. is out with its gimmick for Black Friday.
Tue Nov 26, 2013
Jefferies Group Increases Gilead Sciences Price Target to $80.00
Jefferies Group's price objective points to a potential upside of 7.24% from the stock's previous close.
Analyst Update: Qihoo 360 Technology Co Ltd, The Procter & Gamble Company, and Gilead Sciences, Inc.
The stock has surged about 164% in 2013 to perch at $78.40 , yet skepticism continues to grow toward Qihoo 360 Technology Co Ltd. Short interest soared by 44.8% during the most recent reporting period, and now accounts for a healthy 5.5% of the security's available float.
San Mateo Daily Journal
Gilead protester sues Foster City police
A woman protesting the high price of AIDS drugs at Gilead Sciences last November claims a Foster City police officer knocked her down with a squad car despite the demonstrators following company requests to leave.
Mon Nov 25, 2013
Weekly CFO Sells Highlight: Gilead Sciences Inc., Prudential Financial Inc. ...
Prudential Financial Inc., Ocwen Financial Corporation and Facebook Inc. Gilead Sciences Inc. : SVP and CFO Robin L. Washington Sold 2,869 Shares SVP and CFO Robin L. Washington recently sold 2,869 shares on 11/06/2013 at an average price of $68.63.
Fri Nov 22, 2013
Customer Interaction Solutions
Stocks Build Momentum as S&P Tops 1,800 For First Time
Wall Street consolidated gains ahead of the weekend on Friday as climbing stocks sent the Standard & Poor's 500 index to its first ever close above 1,800.
Bank of America Increased Gilead Sciences PT
On Friday, Bank of America Merrill Lynch analyst Rachel McMinn increased the price objective for Gilead Sciences Inc. from $96 to $107.
The Miami Herald
Gilead gets EU recommendation on hepatitis C drug
Gilead Sciences said Friday that an advisory committee in the European Union is recommending that its hepatitis C drug Sovaldi receive marketing approval.
Stocks to Watch: Hovnanian Enterprises, Inc.(NYSE:HOV), Affymax, Inc. ...
WallStreetAnalyzed.com primarily focuses on NYSE, NASDAQ, and AMEX and occasionally on PINK and OTCBB companies.
Biotech Stock Mailbag: Enanta, Vanda, Pharmacyclics, Top 2014 Stock Catalysts
Your browser is not supported. Please upgrade to one of the following browsers: Google Chrome Mozilla Firefox Apple Safari Microsoft Internet Explorer 8+ You may proceed to the site by clicking here , however some pages might not work correctly.
Thu Nov 21, 2013
HIV and Hepatitis
HIV Integrase Inhibitor Elvitegravir Approved in European Union
The next-generation HIV integrase inhibitor elvitegravir has been approved by the European Commission, to be marketed under the brand name Vitekta, according to an announcement this week from developer Gilead Sciences.
HIV and Hepatitis
KFF Greater Than AIDS Website Explains Affordable Care Act for People with HIV
The Kaiser Family Foundation this month launched a new website to help people with HIV learn more about the Affordable Care Act , popularly known as "Obamacare."
A Value Guru Is Loading Up On These 2 Biotech Stocks
It's a refrain you hear from many fund managers these days after witnessing the market grind ever higher.